Alem D, Garcia-Lavina C, Garagorry F, Centurion D, Farias J, Pazos-Espinosa H
Sci Rep. 2025; 15(1):4393.
PMID: 39910105
PMC: 11799152.
DOI: 10.1038/s41598-025-88307-7.
Boulton D, Hughes C, Vaira V, Del Gobbo A, Palleschi A, Locatelli M
Cell Rep. 2024; 44(1):115120.
PMID: 39723893
PMC: 11837739.
DOI: 10.1016/j.celrep.2024.115120.
Raghuram N, Temel E, Kawamata T, Kozma K, Loch A, Wang W
Breast Cancer Res. 2024; 26(1):86.
PMID: 38807216
PMC: 11134842.
DOI: 10.1186/s13058-024-01842-5.
Yokoyama Y, Iioka H, Horii A, Kondo E
Oncol Lett. 2022; 23(6):173.
PMID: 35497937
PMC: 9019858.
DOI: 10.3892/ol.2022.13293.
Gugnoni M, Manzotti G, Vitale E, Sauta E, Torricelli F, Reggiani F
J Exp Clin Cancer Res. 2022; 41(1):108.
PMID: 35337349
PMC: 8957195.
DOI: 10.1186/s13046-022-02316-2.
Lnc00892 competes with c-Jun to block NCL transcription, reducing the stability of RhoA/RhoC mRNA and impairing bladder cancer invasion.
Ren S, Zhang N, Shen L, Lu Y, Chang Y, Lin Z
Oncogene. 2021; 40(48):6579-6589.
PMID: 34615995
DOI: 10.1038/s41388-021-02033-8.
CG7379 and ING1 suppress cancer cell invasion by maintaining cell-cell junction integrity.
Rusu A, Cornhill Z, Canales Coutino B, Uribe M, Lourdusamy A, Markus Z
Open Biol. 2021; 11(9):210077.
PMID: 34493070
PMC: 8424350.
DOI: 10.1098/rsob.210077.
Discovery of Cellular RhoA Functions by the Integrated Application of Gene Set Enrichment Analysis.
Chun K
Biomol Ther (Seoul). 2021; 30(1):98-116.
PMID: 34429388
PMC: 8724844.
DOI: 10.4062/biomolther.2021.075.
Bartonella type IV secretion effector BepC induces stress fiber formation through activation of GEF-H1.
Wang C, Zhang H, Fu J, Wang M, Cai Y, Ding T
PLoS Pathog. 2021; 17(1):e1009065.
PMID: 33508039
PMC: 7842913.
DOI: 10.1371/journal.ppat.1009065.
Influence of ARHGAP29 on the Invasion of Mesenchymal-Transformed Breast Cancer Cells.
Kolb K, Hellinger J, Kansy M, Wegwitz F, Bauerschmitz G, Emons G
Cells. 2020; 9(12).
PMID: 33291460
PMC: 7762093.
DOI: 10.3390/cells9122616.
A high expression ratio of RhoA/RhoB is associated with the migratory and invasive properties of basal-like Breast Tumors.
Privat M, Cavard A, Zekri Y, Ponelle-Chachuat F, Molnar I, Sonnier N
Int J Med Sci. 2020; 17(17):2799-2808.
PMID: 33162807
PMC: 7645338.
DOI: 10.7150/ijms.43101.
Leukemia-Associated Rho Guanine Nucleotide Exchange Factor and Ras Homolog Family Member C Play a Role in Glioblastoma Cell Invasion and Resistance.
Ding Z, Dong Z, Yang Y, Fortin Ensign S, Sabit H, Nakada M
Am J Pathol. 2020; 190(10):2165-2176.
PMID: 32693062
PMC: 7527857.
DOI: 10.1016/j.ajpath.2020.07.005.
Reduced RhoA expression enhances breast cancer metastasis with a concomitant increase in CCR5 and CXCR4 chemokines signaling.
Kalpana G, Figy C, Yeung M, Yeung K
Sci Rep. 2019; 9(1):16351.
PMID: 31705019
PMC: 6841971.
DOI: 10.1038/s41598-019-52746-w.
Novel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance.
Sridharan S, Howard C, Tilley A, Subramaniyan B, Tiwari A, Ruch R
Front Oncol. 2019; 9:1003.
PMID: 31681564
PMC: 6805781.
DOI: 10.3389/fonc.2019.01003.
RhoC: a fascinating journey from a cytoskeletal organizer to a Cancer stem cell therapeutic target.
Thomas P, Pranatharthi A, Ross C, Srivastava S
J Exp Clin Cancer Res. 2019; 38(1):328.
PMID: 31340863
PMC: 6651989.
DOI: 10.1186/s13046-019-1327-4.
A Novel 3-Dimensional Co-culture Method Reveals a Partial Mesenchymal to Epithelial Transition in Breast Cancer Cells Induced by Adipocytes.
Pallegar N, Garland C, Mahendralingam M, Viloria-Petit A, Christian S
J Mammary Gland Biol Neoplasia. 2018; 24(1):85-97.
PMID: 30474817
DOI: 10.1007/s10911-018-9420-4.
Downregulation of Dock1 and Elmo1 suppresses the migration and invasion of triple-negative breast cancer epithelial cells through the RhoA/Rac1 pathway.
Liang Y, Wang S, Zhang Y
Oncol Lett. 2018; 16(3):3481-3488.
PMID: 30127952
PMC: 6096110.
DOI: 10.3892/ol.2018.9077.
DGC-specific mutations maintained cancer cell survival and promoted cell migration via ROCK inactivation.
Nishizawa T, Nakano K, Harada A, Kakiuchi M, Funahashi S, Suzuki M
Oncotarget. 2018; 9(33):23198-23207.
PMID: 29796182
PMC: 5955407.
DOI: 10.18632/oncotarget.25269.
RhoD Inhibits RhoC-ROCK-Dependent Cell Contraction via PAK6.
Durkin C, Leite F, Cordeiro J, Handa Y, Arakawa Y, Valderrama F
Dev Cell. 2017; 41(3):315-329.e7.
PMID: 28486133
PMC: 5425256.
DOI: 10.1016/j.devcel.2017.04.010.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N
Ann Oncol. 2017; 28(1):128-135.
PMID: 28177460
PMC: 5834036.
DOI: 10.1093/annonc/mdw434.